Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation study

Kristen Hansen, Steve R. Makkar, David Sahner, Josh Fessel, Nathan Hotaling, Hythem Sidky the N3C Consortium
doi: https://doi.org/10.1101/2023.05.26.23290602

Article usage

Article usage: June 2023 to February 2025

AbstractFullPdf
Jun 20234362388
Jul 2023270978
Aug 20231011644
Sep 202372541
Oct 2023691038
Nov 202355425
Dec 202349023
Jan 2024612472366
Feb 202422421577
Mar 202414418350
Apr 202419122223
May 20248914115
Jun 20246623137
Jul 20247516172
Aug 20246416138
Sep 202410825288
Oct 20245719678
Nov 2024769358
Dec 202450863
Jan 2025521473
Feb 2025001
Back to top
Posted June 03, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation study
Kristen Hansen, Steve R. Makkar, David Sahner, Josh Fessel, Nathan Hotaling, Hythem Sidky
medRxiv 2023.05.26.23290602; doi: https://doi.org/10.1101/2023.05.26.23290602
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area